To determine tumor burden, until now, imaging is still being the gold standard to evaluate it on a daily basis in routine practice. However, in the recent years, we started to see that liquid biopsy has started being implemented alongside imaging in order to determine tumor burden. What is positive about liquid biopsy is that it can give us more information. It can tell us information about the molecular aspect, which is, for example, the mutations of the tumor...
To determine tumor burden, until now, imaging is still being the gold standard to evaluate it on a daily basis in routine practice. However, in the recent years, we started to see that liquid biopsy has started being implemented alongside imaging in order to determine tumor burden. What is positive about liquid biopsy is that it can give us more information. It can tell us information about the molecular aspect, which is, for example, the mutations of the tumor. However, we know that liquid biopsy is very expensive. And what is important in our study is that we are trying to understand imaging metrics that help us say that, like, okay, this patient can benefit from both liquid biopsy and imaging. Or in this patient, in this profile, we will still use imaging and that way we can reduce the cost.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.